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Abstract 26 
Background: Recent evidence suggests that YKL-40, also called chitinase-3-like-1, is 27 
involved in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD). 28 
Details of sputum YKL-40 in asthma and COPD, however, remain unknown.  29 
Objectives: To clarify associations of sputum YKL-40 levels with clinical indices in asthma 30 
and COPD. 31 
Methods: Thirty-nine patients with asthma, 14 age-matched never-smokers as controls , 45 32 
patients with COPD, and seven age-matched smokers as controls. Sputum YKL-40 levels 33 
were measured and YKL-40 expression in sputum cells was evaluated by 34 
immunocytochemistry.   35 
Results: Sputum YKL-40 levels were higher in patients with COPD (346 ± 325 ng/ml) than 36 
in their smoker controls (125 ± 122 ng/ml; p < 0.05), but were not significantly different 37 
between patients with asthma (117 ± 170 ng/ml) and their controls (94 ± 44 ng/ml; p = 0.15). 38 
In patients with asthma only, sputum YKL-40 levels were positively correlated with disease 39 
severity (r = 0.34, p = 0.034) and negatively correlated with pre- and post-40 
bronchodilator %FEV1 (r = -0.47 and -0.42, respectively, p < 0.01) and forced mid-41 
expiratory flow (r = -0.48 and -0.46, respectively, p < 0.01). Sputum YKL-40 levels were 42 
positively correlated with sputum neutrophil counts in asthma (r = 0.55, p < 0.001) and with 43 
neutrophil and macrophage counts in COPD (r = 0.45 and 0.65, respectively, p < 0.01). 44 
YKL-40 was expressed in the cytoplasm of sputum neutrophils and macrophages in all 45 
groups. 46 
Conclusions: Elevated sputum YKL-40 reflects airflow obstruction in asthma, whereas the 47 
roles of YKL-40 in the proximal airways in COPD remain to be elucidated.  48 
 49 
50 
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Abbreviation list 51 
CHI3L1: chitinase-3-like-1 52 
BALF: bronchoalveolar lavage fluid 53 
COPD: chronic obstructive pulmonary disease 54 
GOLD: the Global Initiative for Chronic Obstructive Lung Disease guidelines  55 
FEF25-75%: forced mid-expiratory flow  56 
NE: neutrophil elastase 57 
MBP: major basic protein 58 
ICS: inhaled corticosteroids 59 
IL: interleukin 60 
 61 
62 
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Introduction 63 
YKL-40, also known as chitinase-3-like-1 protein (CHI3L1) or human cartilage 64 
glycoprotein-39, is classified as a “mammalian chitinase-like protein,” although it does not 65 
exhibit chitinase activity. YKL-40 is produced in response to inflammatory stimuli and is 66 
secreted by several types of cells, including neutrophils [1], macrophages [2], chondrocytes, 67 
synovial cells [3], and vascular smooth muscle cells [4]. YKL-40 exhibits a potent 68 
proliferative activity in skin and fetal lung fibroblasts [5] and stimulates the migration of 69 
vascular smooth muscle cells and vascular endothelial cells [4, 6]. Serum YKL-40 levels are 70 
elevated in patients with various diseases such as hepatic fibrosis, systemic sclerosis, 71 
osteoarthritis, and idiopathic pulmonary fibrosis [7], suggesting the involvement of YKL-40 72 
in inflammatory processes and tissue remodeling [8]. 73 
Asthma and chronic obstructive pulmonary disease (COPD) are characterized by 74 
airway inflammation and remodeling that lead to reversible or irreversible airflow 75 
obstruction. Recent studies have shown that YKL-40 is involved in the pathophysiology of 76 
asthma [9-12] and COPD [13]. Serum YKL-40 levels were higher in patients with asthma [9] 77 
and COPD [13] than in healthy controls and were correlated with airflow obstruction and 78 
disease severity. Serum YKL-40 levels were higher in patients with asthma with 79 
exacerbations than those in a stable condition [11]. In patients with COPD, elevated YKL-40 80 
levels in the bronchoalveolar lavage fluid (BALF) have been reported to be associated with 81 
airflow obstruction. In the case of asthma, Kuepper et al. showed that YKL-40 levels in the 82 
BALF of patients with allergic asthma were increased after administration of segmental 83 
allergen challenges [12]. However, associations of YKL-40 levels in the airways with 84 
clinical indices in asthma remain largely unknown. 85 
Sputum YKL-40 levels may provide more relevant and specific information on 86 
asthma than that provided by levels found in blood samples. Therefore, we investigated the 87 
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relationships of sputum YKL-40 levels with clinical indices in asthma and assessed the 88 
similarities and differences in sputumYKL-40 associations with disease pathophysiology 89 
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Methods and Materials 94 
Subjects 95 
For this cross-sectional study, 39 patients with stable asthma who regularly visited our 96 
outpatient asthma and cough clinic were enrolled. Asthma was diagnosed according to the 97 
American Thoracic Society criteria [14] based on a history of recurrent episodes of wheezing 98 
and chest tightness, with or without cough, and documented airway reversibility with a 99 
bronchodilator or hyperresponsiveness to inhaled methacholine. Severity was defined 100 
according to the step classification of the Global Initiative for Asthma guidelines, as revised 101 
in 2002 [15], and classified as follows: mild intermittent (step 1), mild persistent (2), 102 
moderate persistent (3), and severe persistent (4). All patients with asthma were lifelong 103 
never-smokers.  104 
Patients with COPD (n = 45) as defined by the Global Initiative for Chronic 105 
Obstructive Lung Disease guidelines (GOLD) 2003 [16] who had a history of chronic 106 
respiratory symptoms, such as cough and sputum with or without breathlessness and had a 107 
post-bronchodilator FEV1/forced vital capacity (FVC) ratio of less than 0.7 and who 108 
regularly visited our outpatient COPD clinic were recruited. Patients were either current (n = 109 
10: mean of 62.9 ± 26.3 pack-years) or former smokers (n = 35; 62.7 ± 28.8 pack-years). 110 
Typical emphysematous changes were observed in all patients with COPD on chest 111 
computed tomography scans. Among these, six were considered to have chronic bronchitis 112 
that was defined by the presence of sputum production for a consecutive 3 months for 2 113 
years in a row. The conditions of both asthma and COPD patients were stable, and they had 114 
been free of exacerbations for 4 weeks or more. Patients were excluded who had any active 115 
malignant diseases within 5 years, connective tissue diseases, infectious diseases, or active 116 
respiratory disorders other than asthma or COPD.  117 
We recruited 14 age-matched healthy never-smokers as controls for patients with 118 
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asthma and seven age-matched former smokers without COPD as controls for patients with 119 
COPD from our hospital. The research protocol was approved by the Ethics Committee of 120 
Kyoto University, and written informed consent was obtained from all subjects. 121 
 122 
Sputum induction and processing  123 
Sputum induction and processing were performed as described by Pin [17], with slight 124 
modifications [18]. In brief, the subjects were pre-medicated with inhaled salbutamol (200 125 
μg). They then inhaled hypertonic (3%) saline solution, administered by an ultrasonic 126 
nebulizer (MU-32, Azwell Inc, Osaka, Japan) for 15 minutes. Adequate sputum plugs were 127 
separated from saliva and first treated with 0.1% dithiothreitol (Sputasol, Oxiod Ltd., 128 
Hampshire, UK), followed by the same volume of Dulbecco’s phosphate buffered saline 129 
(PBS). After centrifugation, sputum supernatants were stored at -80℃. Cell differentials 130 
were determined by counting at least 400 non-squamous cells stained by the May-Grünwald-131 
Giemsa method. 132 
 133 
Measurement of YKL-40 levels in sputum supernatants 134 
YKL-40 levels in sputum supernatants were measured using an enzyme-linked 135 
immunosorbent assay kit (Quidel, San Diego, USA) following the manufacturer’s 136 
instructions. The detection limit of this assay was 10 ng/ml. Values below this threshold were 137 
assigned values of 10 ng/ml before adjusting for the dilution with dithiothreitol and PBS. A 138 
spike-back analysis that used exogenous YKL-40 resulted in greater than 80% recovery.  139 
 140 
Specific IgE measurement 141 
In patients with asthma and  COPD, serum allergen-specific IgE antibodies were detected 142 
with a capsulated hydrophilic carrier polymer radioallergosorbent test fluoroenzyme 143 
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immunoassay (Phadia, Uppsala, Sweden) at an external laboratory (Mitsubishi Kagaku Bio-144 
Clinical Laboratories, Kyoto, Japan), for mixed moulds, house-dust mite, cat dander, dog 145 
dander, Japanese cedar pollen, mixed grass pollens, and mixed weed pollens. Atopy was 146 
determined based on the detection of at least one allergen-specific IgE antibody. 147 
 148 
Pulmonary function 149 
We measured FVC, FEV1, and forced mid-expiratory flow (FEF25-75%) using a Chestac-65V 150 
(Chest MI Corp., Tokyo, Japan). Spirograms were obtained in triplicate, and the best of 3 151 
reproducible measurements was recorded, as recommended by the American Thoracic 152 
Society/European Respiratory Society [19]. 153 
 154 
Immunostaining  155 
Sputum cells from at least three samples obtained from patients with asthma, those with 156 
COPD and their age-matched controls were used for immunostaining. After adjusting for the 157 
cell number, sputum cells were mounted on slides by cytocentrifugation, air-dried, fixed in 158 
acetone/methanol (60:40), and stored at -20℃ until immunostaining. For double 159 
immunostaining, samples were first blocked with 5% BSA in PBS for non-specific binding. 160 
The slides were then incubated either with a rabbit polyclonal antibody against human YKL-161 
40 (33 μg/ml) (Quidel) or rabbit IgG (Dako, Glostrup, Denmark) at the same concentration 162 
as a control and either a monoclonal mouse antibody against human neutrophil elastase (NE) 163 
(Dako), CD68 (Dako), or major basic protein (MBP) (Chemicon, Temecula, CA, USA) or 164 
mouse IgG  (Sigma-Aldrich, Tokyo, Japan) in PBS containing 1% BSA. Concentrations of 165 
mouse IgG used for negative controls are shown in Table 1. After rinsing in PBS, samples 166 
were incubated with Alexa Fluor 488 donkey anti-rabbit IgG (Invitrogen Corp, Carlsbad, 167 
CA, USA) and Alexa Fluor 546 goat anti-mouse IgG (Invitrogen). A fluorescence 168 
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microscope was used for immunocytochemical evaluations. 169 
Positive staining was detected as green for the YKL-40 antigen and red for the NE, 170 
CD68, and MBP antigens.  171 
 172 
Statistical analysis  173 
A Mann-Whitney U-test was used to compare 2 groups. For comparisons of nominal data, a 174 
chi-squared test or Fisher’s exact test was used. Correlations were analyzed using 175 
Spearman’s rank correlation test. P-values of < 0.05 were considered significant. Differences 176 
among 3 groups were first examined using a Kruskal-Wallis test. Results are given as means 177 
± SDs, unless otherwise stated. Statistical analysis was performed using JMP 6.0 (SAS 178 
Campus Drive, Cary, NC, USA). 179 
  10 
RESULTS 180 
Characteristics of patients with asthma and COPD and their age-matched controls 181 
Characteristics, results of pulmonary function tests and sputum cell differentials of 39 182 
patients with asthma and their age-matched controls are shown in Table 2. In the asthma 183 
group, differences in patient characteristics other than serum IgE levels between atopic 184 
(median serum IgE = 120 IU/ml) and non-atopic patients (median serum IgE = 39 IU/ml; p = 185 
0.037) were not statistically significant. The findings for 45 patients with COPD and their 186 
age-matched smoker controls are shown in Table 3. Differences in patient characteristics 187 
between COPD patients with and without chronic bronchitis were not statistically 188 
significant. When patients with asthma and COPD were compared, patients with COPD were 189 
predominantly males and older than those with asthma, and more patients with asthma (n = 190 
38) received inhaled corticosteroids (ICS) than did COPD patients (n = 12) (p < 0.001), and 191 
more patients with asthma used theophylline (9 patients with asthma vs 1 patient with COPD 192 
patient, p = 0.005).  Patients with COPD showed severer airflow limitation (for FEV1/FVC 193 
and %FEF25-75%, p<0.001; for %FEV1, p=0.042) and showed greater number of macrophages 194 
and neutrophils in induced sputum (p=0.020 and p < 0.001, respectively) than those with 195 
asthma. 196 
 197 
Sputum YKL-40 levels in patient and control groups 198 
Sputum YKL-40 levels were significantly higher in patients with COPD (346 ± 325 ng/ml) 199 
than in their smoker controls (125 ± 122 ng/ml; p = 0.011) (Fig 1a), whereas there was no 200 
significant difference between patients with asthma (n=39, 117 ± 170 ng/ml) and their 201 
controls (94 ± 44 ng/ml) (p = 0.15).  In 14 patients with asthma and two smoker controls, 202 
sputum YKL-40 levels were below the detection limit. Atopic status of patients with asthma 203 
did not affect sputum YKL-40 levels (atopic asthma 105 ± 125 ng/ml, non-atopic asthma 155 204 
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± 271 ng/ml; p = 0.88) (Fig 1b). For patients with COPD, differences in sputum YKL-40 205 
levels between those who had chronic bronchitis (n = 6, 471 ± 384 ng/ml) and those who did 206 
not (327 ± 316 ng/ml; p = 0.19) were not statistically significant. When patients with asthma 207 
and COPD were compared, patients with COPD showed higher sputum YKL-40 levels than 208 
those with asthma (p < 0.001). 209 
 210 
Relationships between YKL-40 sputum levels and clinical indices in patients with 211 
asthma and COPD 212 
In patients with asthma, YKL-40 sputum levels were positively correlated with disease 213 
severity (r = 0.34, p = 0.034) (Fig 2) and maintenance doses of ICS (r = 0.33, p = 0.045), 214 
whereas in patients with COPD, there was no significant correlation between YKL-40 215 
sputum levels and the GOLD stages (r = -0.24, p = 0.11) or maintenance doses of ICS (r = 216 
0.23, p = 0.13). In patients with asthma, sputum YKL-40 levels were not associated with 217 
gender (males 148 ± 238 ng/ml, females 93 ± 74 ng/ml, p = 0.88). In either patient group, 218 
sputum YKL-40 did not associate with age (asthma, r = -0.09, p = 0.50; COPD, r = 0.22, p = 219 
0.15). Moreover, body mass index, serum IgE levels, concurrent chronic sinusitis, and use of 220 
theophylline did not affect sputum YKL-40 levels (data not shown). In patients with asthma, 221 
sputum YKL-40 levels were negatively correlated with both pre- and post-bronchodilator 222 
FEV1 (Fig 3A, B) and FEF25-75% values (Fig 4A, B). In contrast, in COPD patients and the 223 
controls of both patient groups, no correlations were observed between YKL-40 sputum 224 
levels and measures of pulmonary function (Fig 3C, D and Fig 4C, D for COPD; data not 225 
shown for controls). 226 
 227 
Relationships between YKL-40 sputum levels and sputum inflammatory cells: 228 
Immunocytochemical examinations of sputum inflammatory cells 229 
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In patients with asthma, sputum YKL-40 levels were correlated only with the numbers of 230 
sputum neutrophils, while in COPD patients, sputum YKL-40 levels were correlated with the 231 
numbers of sputum macrophages and neutrophils (Fig 5). When the 14 patients with asthma 232 
who showed sputum YKL-40 levels under the detection limit were compared to the 233 
remaining 25  patients with asthma, the former showed fewer sputum neutrophils (10.6 ± 234 
29.9 × 10
5∙g−1), in addition to higher pre-bronchodilator FEV1 (97.0 ± 20.1%) and FEF25–75% 235 
(61.9 ± 26.5%) values than the remaining 25 patients with asthma (12.8 ± 17.7 × 10
5∙g−1; 236 
82.3 ± 22.6%; 46.6 ± 30.8%, respectively; p < 0.05 for all comparisons). No significant 237 
correlations were observed between sputum YKL-40 levels and sputum eosinophil counts in 238 
patients with asthma or in patients with COPD (r = 0.12, p = 0.47; r = 0.25, p = 0.10, 239 
respectively). There were no significant correlations between sputum YKL-40 levels and 240 
neutrophil, macrophage or eosinophil counts in the controls of both patient groups (data not 241 
shown).  242 
The presence or absence of YKL-40 in CD68- or NE- positive cells in at least three 243 
samples obtained from patients with asthma, those with COPD, and their controls was 244 
examined immunocytochemically. The presence or absence of YKL-40 in MBP-positive 245 
cells was examined in patients with asthma. In all examined subjects, YKL-40 was positive 246 
for cells that were positive for NE or CD68 antigens, but was negative for cells that were 247 
positive for MBP (Fig 6). There were no apparent qualitative differences in the expression of 248 
YKL-40 in neutrophils or macrophages between patients with asthma and COPD and their 249 
controls. Apparent effects of age, gender and medications on YKL-40 expression were 250 
absent.  251 
252 
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DISCUSSION 253 
To our knowledge, this is the first study to examine sputum YKL-40 levels in patients with 254 
asthma and COPD. Sputum YKL-40 levels were elevated in patients with COPD compared 255 
with their age-matched smoker controls but did not differ between patients with asthma and 256 
their age-matched controls. In patients with asthma, sputum YKL-40 levels were positively 257 
correlated with disease severity and sputum neutrophil counts and were negatively correlated 258 
with measures of pulmonary function. In patients with COPD, no significant associations 259 
were found, except for those of sputum YKL-40 levels with macrophage and neutrophil 260 
counts. 261 
Recent evidence suggests that chitinases [20] and chitinase like proteins including 262 
YKL-40 [21] are involved in the pathophysiology of asthma. Chupp et al. reported that 263 
serum YKL-40 levels were increased in patients with asthma and that these levels were 264 
positively correlated with disease severity (p value for trend = 0.02) and sub-basement 265 
membrane thickness in bronchial biopsy (r = 0.51, p = 0.003) and were negatively, although 266 
weakly, correlated with the levels of FEV1 (r = -0.22, p = 0.01) [9]. The same researchers 267 
showed that the CHI3L1 gene encoding YKL-40 had a single nucleotide polymorphism in its 268 
promoter region that was associated with elevated YKL-40 protein levels, asthma 269 
susceptibility, airway hyperresponsiveness, and impaired lung function [10]. Our results 270 
have confirmed and expanded upon previous findings. 271 
In agreement with the results of the serum sample analysis performed by Chupp et al. 272 
[9], sputum YKL-40 levels in patients with asthma correlated with disease severity and 273 
degree of airflow obstruction. To evaluate irreversible functional changes, we recruited 274 
patients who were in a stable condition and also evaluated post-bronchodilator indices of 275 
pulmonary function. Moreover, unlike previous studies, we examined sputum samples; these 276 
samples provide more direct information on airway conditions than that provided by serum 277 
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samples. Consequently, correlations of YKL-40 levels with both pre- and post-FEV1 values, 278 
as well as FEF25–75% values, were stronger than those reported in a previous study on asthma 279 
[9]; this showed that YKL-40 in the airways was associated with airway remodelling in 280 
asthma.  281 
Although the biologic functions of YKL-40 have not been completely understood, 282 
YKL-40 may be involved in persistent airway inflammation as well as tissue repair in 283 
asthma, as described below. Within 10 min after administration of segmental allergen 284 
challenges, the YKL-40 levels in BALF samples obtained from patients with allergic asthma 285 
increased and remained elevated for up to 24 h [12]. YKL-40 is induced by the pro-286 
inflammatory cytokines tumour necrosis factor-α and interleukin (IL)-1 [22], as well as by 287 
IL-13 [23], which is a potential key regulator of asthma [24], and COPD [25]. Lee et al. 288 
showed that mice with null mutations of BRP-39 (BRP-39
-/-
), a mouse homologue of YKL-289 
40, showed markedly diminished antigen-induced Th2 responses and decrease in the ability 290 
of IL-13 to induce tissue inflammation and fibrosis [23]. YKL-40 also binds to collagen I 291 
and regulates collagen fibril formation [26]. These findings indicate potential biologic roles 292 
played by YKL-40 in airway inflammation and tissue remodelling in asthma. 293 
In all groups, YKL-40 was expressed in the cytoplasm of sputum neutrophils, as well 294 
as macrophages. This finding was consistent with previous findings that showed the 295 
presence of YKL-40 in neutrophils and macrophages in BALF samples obtained from 296 
patients with COPD [13] and those with severe asthma [9]. We found new associations of 297 
sputum YKL-40 levels with sputum cell types. Sputum YKL-40 levels were correlated with 298 
sputum neutrophil counts in patients with asthma and with both macrophage and neutrophil 299 
counts in patients with COPD. In addition, patients with asthma who showed sputum YKL-300 
40 levels below the detection limit revealed lower sputum neutrophil counts than the 301 
remaining asthmatic patients. This association of sputum YKL-40 levels with neutrophil 302 
  15 
counts and expression of YKL-40 in sputum neutrophils suggests that neutrophils are the 303 
major cell source of sputum YKL-40 in asthma; this may partly explain the lack of a 304 
difference in sputum YKL-40 levels between asthmatic patients and their age-matched 305 
controls and the fact that a significant number of patients with asthma showed sputum YKL-306 
40 levels below the detection limit. Neutrophilic airway inflammation plays an important 307 
role in a subgroup of patients with asthma [27] and is correlated with fixed airflow 308 
obstruction [28, 29] but is not a predominant feature in the patient population as a whole. In 309 
fact, sputum neutrophil counts were similar between patients with asthma and their age-310 
matched controls in our study. Although correlations do not imply causation, in the case of 311 
asthma, YKL-40 in the airways may contribute to airflow obstruction in association with 312 
neutrophilic inflammation.  313 
Recently, Tang et al. reported a moderate negative correlation of serum YKL-40 314 
levels with %FEV1 (r = -0.44, p = 0.001) and a mild correlation with peripheral blood 315 
eosinophil percentages (r = 0.27, p = 0.032) in patients with asthma [11]. In addition, 316 
Kuepper et al. reported that  YKL-40 levels in BALF of patients with allergic asthma after 317 
administration of segmental allergen challenges were positively correlated with eosinophil 318 
counts in the BALF [12]. In our study, sputum YKL-40 levels were not correlated with 319 
sputum eosinophil counts. Our results, however, do not contradict previous findings because 320 
the asthmatic patients in our study were in a stable condition, and 74% of the patients in 321 
Tang’s study had exacerbation attacks [11]. Moreover, neutrophilic and eosinophilic airway 322 
inflammation are not reciprocally exclusive in asthma, particularly in patients with worse 323 
asthma control [30]. 324 
 In our study, the atopic status of patients with asthma did not affect sputum YKL-40 325 
levels. Association studies of the CHI3L1 gene with atopy have shown inconsistent findings; 326 
some single nucleotide polymorphisms were associated with risks for atopy [31], whereas 327 
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others showed protective effects [32]. Possible associations of YKL-40 with atopy should be 328 
further clarified. 329 
Unexpectedly, we found no correlations between sputum YKL-40 levels and clinical 330 
indices, including the presence of chronic bronchitis, in patients with COPD. This finding 331 
was in contrast to the findings of Létuve et al., who reported negative correlations of BALF 332 
YKL-40 levels with FEV1 values and carbon monoxide diffusion capacity in patients with 333 
COPD. They showed that YKL-40 contributed to the synthesis of pro-inflammatory and 334 
fibrogenic chemokines by alveolar macrophages in COPD [13]. The discrepancies between 335 
our findings and the findings of Létuve at al. cannot be fully explained but may be attributed 336 
to better %FEV1 values in our study than in the study of Létuve et al. (the median %FEV1 337 
was 78.8% in our study and 61.5% in theirs) [13] and different sample sources, i.e., sputum 338 
vs. BALF. Sputum is derived from more proximal airways and contains fewer macrophages 339 
than those present in BALF. In addition to the lack of differences in sputum YKL-40 levels 340 
between COPD patients with and without chronic bronchitis, the discrepancy between our 341 
findings in COPD and asthma may suggest that YKL-40 in the airways is differently 342 
involved in the pathogenesis of COPD and asthma in terms of the locations, in particular, 343 
that are predominantly involved, although the findings in asthma and COPD in this study 344 
cannot be compared directly because there were significant differences in patients’ 345 
characteristics such as age and gender between the two patient groups. 346 
Our study has several limitations. First, the number of age-matched smoker controls 347 
was small because older smokers without airflow limitation were difficult to find and recruit. 348 
However, the difference in sputum YKL-40 levels between patients with COPD and smoker 349 
controls was significant. Second, we did not assess possible relationships between clinical 350 
indices and the degrees of YKL-40 expression in sputum cells because cells obtained from 351 
sputum samples were inadequate for quantifying the extent of YKL-40 expression. The 352 
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number of epithelial cells, which also express YKL-40 in severe asthma [9], was not 353 
assessed because the epithelial cells in the sputum were too few to be analyzed. Last, 354 
assigning values of 10 ng/ml when sputum YKL-40 levels were below this threshold may 355 
have overestimated actual sputum YKL-40 levels. Our findings, however, did not alter even 356 
when the values were assigned to 0.1 ng/ml (data not shown). The associations of sputum 357 
YKL-40 levels with clinical indices in asthma were robust. 358 
In conclusion, elevated sputum YKL-40 levels reflect airflow obstruction only in 359 
asthma. Further analysis may be required to determine the roles of YKL-40 in the proximal 360 
airways in COPD. 361 
362 
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 471 
Figure legends 472 
Figure 1. (a) Sputum YKL-40 levels between patients with COPD and their age-matched 473 
smoker controls. (b) Sputum YKL-40 levels between patients with atopic asthma and non-474 
atopic asthma and their age-matched controls. p = 0.34 by Kruskal Wallis test. Logarithmic 475 
results are shown for sputum YKL-40 levels. Horizontal bars indicate mean values. 476 
 477 
Figure 2. Correlation of sputum YKL-40 levels with disease severity in asthma (r = 0.34, p = 478 
0.034).  479 
 480 
Figure 3. Correlations of sputum YKL-40 levels with pre- and post-bronchodilator %FEV1 in 481 
patients with asthma (A, B) and COPD (C, D).  482 
 483 
Figure 4. Correlations of sputum YKL-40 levels with pre- and post-bronchodilator %FEF25-484 
75% in patients with asthma (A, B) and COPD (C, D).  485 
 486 
Figure 5. Correlations of sputum YKL-40 levels with sputum neutrophil counts (A, C) and 487 
macrophage counts (B, D) in patients with asthma (A, B) and COPD (C, D).  488 
Logarithmic results are given for sputum YKL-40 levels, and sputum neutrophil and 489 
macrophage counts.  490 
 491 
Figure 6. Representative micrographs of sputum cytospin preparations. At least three 492 
samples obtained from patients and their age-matched controls are presented (Fig 6-1, 493 
healthy controls; Fig 6-2 and -4, atopic asthma; Fig 6-3 and -4, non-atopic asthma; Fig 6-5, 494 
smoker controls; Fig 6-6, COPD). M = male, F = female. 495 
  25 
Double stained (a) with antibody against CD68 and negative control using rabbit IgG; (b) 496 
with antibodies against CD68 and YKL-40; (c) with antibody against neutrophil elastase 497 
(NE) and negative control using rabbit IgG; (d) with antibodies against NE and YKL-40; (e) 498 
with negative control using mouse IgG and rabbit IgG; (f) with antibody against major basic 499 
protein (MBP) and negative control using rabbit IgG; (g) with antibodies against MBP and 500 
YKL-40. 501 
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r = -0.47, p = 0.003
r = -0.42, p = 0.009
r = 0.27, p = 0.072
































































































(A) Pre-bronchodilator %FEF25-75% (%) (C) Pre-bronchodilator %FEF25-75% (%)
(B) Post-bronchodilator %FEF25-75% (%) (D) Post-bronchodilator %FEF25-75% (%)Fig. 4
r = -0.48, p = 0.002
r = -0.46, p = 0.003
r = 0.20, p = 0.19
































































































(A) Log sputum neutrophil numbers /g
(B) Log sputum macrophage numbers /g
(C) Log sputum neutrophil numbers /g
(D) Log sputum macrophage numbers /g
Fig. 5
r = 0.55, p < 0.001
r = 0.17, p = 0.29
r = 0.45, p = 0.002
r = 0.65, p < 0.001
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Table 1. Concentrations of mouse IgG used for negative controls 505 
Mouse monoclonal antibody Concentration of mouse IgG 
Anti-neutrophil elastase 0.07 µg/ml 
Anti-CD68 1.25 µg/ml 
 506 
507 
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  508 
Table 2. Characteristics and findings of patients with asthma and their age-matched controls 509 
 
Asthma 
N = 39 
Age-matched 
Control 
N = 14 
 
p value 
Male, n 12 5 0.75 
Age, yrs 58 (14) 51 (14) 0.47 
Body mass index, kg/m2 23.7 (3.3) 22.0 (2.7) 0.083 
Disease duration (years) 16.3 (17.2) - - 
Disease severity * 1/17/12/9 - - 
Co-morbidity of 
chronic sinusitis 
7 - - 
Atopy †, n 22 - - 
Serum IgE, IU/ml 118 (8-1276) - - 
Dose of inhaled 
steroids, μg/day ‡ 
897 (607) - - 
Pre-bronchodilator 
   
FEV1/FVC, % 
67.9 (11.8) 81.3 (5.9) < 0.001 
FEV1, % predicted 
87.6 (22.6) 105.8 (12.6) 0.003 
FEF25-75%, %predicted 
52.1 (29.9) 93.3 (27.9) < 0.001 
Post-bronchodilator    
FEV1/FVC, % 
69.5 (11.6) 82.2 (6.3) < 0.001 
FEV1, % predicted 
90.3 (21.9) 108.4 (12.6) 0.006 
FEF25-75%, %predicted 
57.3 (32.1) 96.7 (31.6) < 0.001 
Induced Sputum    
Macrophages × 105・g-1 4.6 (5.3) 6.4 (7.3) 0.76 
Neutrophils ×105・g-1 
12.0 (22.5) 6.6 (4.5) 0.55 
Eosinophils ×105・g-1 2.6 (6.4) 0.1 (0.3) < 0.001 
 510 
Results are means (SD) except for IgE, median (range).  511 
*Step classification of the Global Initiative for Asthma (1/2/3/4)  512 
†Data are missing for 4 patients with asthma. 513 
‡Dose equivalent to chlorofluorocarbon beclomethasone. The dose for patients untreated with 514 
inhaled corticosteroids was assigned 0 μg/day.  515 
 516 
517 
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N = 45 
Age-matched 
smoker control 




Male, n 45 6 0.13 
Age, yrs 72 (9) 67 (5) 0.13 
Body mass index, kg/m2 22.0 (2.7) 22.6 (2.3) 0.82 
Lifetime smoking, 
former: current 
35: 10 5: 2 0.66 
Pack-years 62.7 (27.9) 36.3 (12.8) 0.004 
Disease duration (years) 6.2 (5.2) - - 
Disease severity * 20/20/5/0 - - 
Co-morbidity of 
chronic sinusitis 
4 - - 
Atopy, n 14 - - 
Serum IgE, IU/ml 130 (5-1500) - - 
Dose of inhaled 
steroids, μg/day ‡ 
364 (637) - - 
Pre-bronchodilator    
FEV1/FVC, % 
51.5 (10.7) 73.8 (9.1) <0.001 
FEV1, % predicted 
77.3 (21.1) 96.1 (8.6) 0.018 
FEF25-75%, %predicted 
23.9 (9.3) 65.3 (22.7) <0.001 
Post-bronchodilator    
FEV1/FVC, % 
52.9 (11.3) 76.7 (7.4) <0.001 
FEV1, % predicted 
83.4 (19.9) 100.2 (8.1) 0.033 
FEF25-75%, %predicted 
27.1 (11.3) 74.0 (17.4) <0.001 
Induced Sputum    
Macrophages × 105・g-1 9.4 (11.3) 2.9 (3.2) 0.033 
Neutrophils ×105・g-1 26.9 (38.0) 8.8 (8.7) 0.046 
Eosinophils ×105・g-1 1.5 (2.6) 0.5 (0.6) 0.13 
 520 
Results are means (SD) except for IgE, median (range). 521 
*Stages of GOLD criteria stages for COPD (Ⅰ/Ⅱ/Ⅲ/Ⅳ) 522 
‡Dose equivalent to chlorofluorocarbon beclomethasone. The dose for patients untreated with 523 
inhaled corticosteroids was assigned 0 μg/day.  524 
 525 
 526 
